scholarly journals Attenuated metabolic and increased renal effects of angiotensin II (ang II) in early type 2 diabetes mellitus (NIDDM)

1997 ◽  
Vol 10 (4) ◽  
pp. 15A
Author(s):  
D FLISER
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Angiotensin Ii ◽  
Ang Ii ◽  
Early Type ◽  
Renal Effects

Assessment of Adverse Renal Effects in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Ertugliflozin

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1168-P ◽  
Author(s):  
SHRITA M. PATEL ◽  
MARY A. HICKMAN ◽  
ROBERT FREDERICH ◽  
BRETT LAURING ◽  
STEVEN TERRA ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Renal Effects

Altered action of angiotensin II in patients with type 2 diabetes mellitus of recent onset

1997 ◽  
Vol 15 (3) ◽  
pp. 293-299 ◽  
Author(s):  
Danilo Fliser ◽  
Christine Keller ◽  
Philipp Bahrmann ◽  
Edward Franek ◽  
Hans Schreckling ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Angiotensin Ii ◽  
Recent Onset

Angiotensin-II Receptor Antagonist Alleviates Non-alcoholic Fatty Liver in KKAy Obese Mice with Type 2 Diabetes

2006 ◽  
Vol 34 (3) ◽  
pp. 297-302 ◽  
Author(s):  
F Yu ◽  
T Takahashi ◽  
J Moriya ◽  
K Kawaura ◽  
J Yamakawa ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Angiotensin Ii ◽  
Obese Mice ◽  
Angiotensin Ii Receptor ◽  
Angiotensin Ii Receptor Antagonist ◽  
Alcoholic Fatty Liver ◽  
Adiponectin Mrna

We examined the effects of the angiotensin-II receptor antagonist candesartan on non-alcoholic fatty liver (NAFL) and circulating adiponectin concentrations in KKAy obese mice with type 2 diabetes mellitus. The KKAy mice were randomly assigned to receive either candesartan at a once-daily dose of 10 mg/kg ( n = 5) or placebo ( n = 5). The differences in liver weight, histological evaluation of hepatic lipid infiltration, serum adiponectin concentration and hepatic adiponectin mRNA levels between the two groups were determined on day 7 after treatment was initiated. Candesartan-treated mice demonstrated significantly lower liver weights and reduced lipid droplets in hepatic cells compared with control mice. The circulating adiponectin levels and hepatic expression of adiponectin mRNA were significantly higher in candesartan-treated mice than control mice. These results suggest that candesartan might alleviate NAFL through elevation of circulating adiponectin levels in KKAy obese mice with type 2 diabetes mellitus.

scholarly journals Renal effects of canagliflozin in type 2 diabetes mellitus

2015 ◽  
Vol 31 (12) ◽  
pp. 2219-2231 ◽  
Author(s):  
Vlado Perkovic ◽  
Meg Jardine ◽  
Ujjwala Vijapurkar ◽  
Gary Meininger
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Renal Effects

scholarly journals Visual changes in patients with early type 2 diabetes mellitus without diabetic retinopathy due to possible subclinical ischemia

2019 ◽  
Vol 97 (S263) ◽  
Author(s):  
María José Vicente ◽  
Elisa Vilades ◽  
Elvira Orduna ◽  
Beatriz Cordón ◽  
Javier Pérez‐Velilla ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diabetic Retinopathy ◽  
Early Type ◽  
Visual Changes
Sign in / Sign up

Export Citation Format

Share Document